The SphK1-S1P-S1PR1 axis has emerged to be one of the major targets in developing anticancer agents against breast cancer, and quite a few SphK1 inhibitors such as SK1-I and S1PR1 antagonists such as NIBR0213 have been developed [24, 25]. Here, SPHK1 is linked to breast carcinoma.